AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02257970
Drug: Ketoprofen
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02257970
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match ketoprofen.
Trial: NCT04158362
Drug: Capecitabine tablets
RxNorm normalized name: Capecitabine Tablets
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine is given orally at a dose of 2000 to 2500 mg/m² daily for 14 days followed by a 7-day rest period every 3 weeks
Trial: NCT00490828
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone
Trial: NCT02136927
Drug: SPARC1210
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02201953
Drug: SOF/VEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400/100 mg FDC tablet administered orally once daily
Trial: NCT02201953
Drug: SOF
RxNorm normalized name: Kasof
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg tablet administered orally once daily
Trial: NCT00883896
Drug: ILV-094
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1: ILV-094 100 mg SC every 4 weeks (alternating ILV-094 100 mg and placebo every 2 weeks) X 10 weeks.
Trial: NCT00883896
Drug: ILV-094
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1: ILV-094 100 mg SC every 2 weeks X 10 weeks.
Trial: NCT00883896
Drug: ILV-094
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 2: ILV-094 200 mg SC every 2 weeks X 10 weeks
Trial: NCT04632316
Drug: Cyclophosphamide-Fludarabine (Cy/Flu)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lymphodepleting conditioning regimen
Trial: NCT04632316
Drug: oNKord®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allogeneic ex vivo-generated Natural Killer (NK) cells from CD34+ umbilical cord blood progenitor cells
Trial: NCT00504816
Drug: GSK189075
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given with Brevicon to determine any effects of GSK189075 on Brevicon PK.
Trial: NCT00005803
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04138758
Drug: LABA/ICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting beta2-agonist and Inhaled corticosteroids (LABA and ICS)
Trial: NCT03294707
Drug: AG10 oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active single ascending dose
Trial: NCT03294707
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo single dose
Trial: NCT03904849
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral solution
Trial: NCT02096601
Drug: LD/CD SC solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa/carbidopa SC solution
Trial: NCT04679064
Drug: Pegylated liposomal doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy drug
Trial: NCT03088306
Drug: Standard analgesia use [Volatile Anesthesia]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A protocol directed and clinically appropriate post-operative analgesia. In this study, standard post-operative analgesia is defined as: oxygen, volatile anesthesia, fentanyl, hydromorphone.
Trial: NCT03088306
Drug: Standard analgesia use [Fentanyl]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A protocol directed and clinically appropriate post-operative analgesia. In this study, standard post-operative analgesia is defined as: oxygen, volatile anesthesia, fentanyl, hydromorphone.
Trial: NCT03088306
Drug: Multi-modal pain management [Acetaminophen + Gabapentin]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of acetaminophen (1 gm po) plus gabapentin (600-1200 mg po) in the preparation area prior to surgery; pre-induction opioid titration with fentanyl until pain is relieved and/or respiratory depression ensues; intravenous ketamine (1 mg/kg load prior to incision then 10 mcg/kg/min) during surgery; acetaminophen, valium plus gabapentin during hospitalization; and prescription for acetaminophen, valium plus gabapentin at discharge.
Trial: NCT03088306
Drug: Multi-modal pain management [Fentanyl]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of acetaminophen (1 gm po) plus gabapentin (600-1200 mg po) in the preparation area prior to surgery; pre-induction opioid titration with fentanyl until pain is relieved and/or respiratory depression ensues; intravenous ketamine (1 mg/kg load prior to incision then 10 mcg/kg/min) during surgery; acetaminophen, valium plus gabapentin during hospitalization; and prescription for acetaminophen, valium plus gabapentin at discharge.
Trial: NCT01695226
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pre-operative celecoxib (400 mg) twice daily for two to three weeks
Trial: NCT01695226
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pre-operative placebo twice daily for two to three weeks
Trial: NCT04035824
Drug: Gastrodia and Uncaria granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients allocated to the intervention group take 10g of Gastrodia and Uncaria granule each time, twice per day, and for two months.
Trial: NCT04035824
Drug: Placebo of Gastrodia and Uncaria granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients allocated to the control group take 10g of placebo of Gastrodia and Uncaria granule each time, twice per day, and for two months. The placebo has similar appearance and smell to genuine drug but has no effective anti-hypertensive agents.
Trial: NCT03431688
Drug: PBMT
RxNorm normalized name: Photobiomodulation Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment with PPI, metonidazole, bismuth, tetracyclin
Trial: NCT04311515
Drug: PU-AD
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PU-AD 30mg daily for 6mos
Trial: NCT01887327
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo administered by IM injection
Trial: NCT04311515
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 30mg daily for 6mos
Trial: NCT02172274
Drug: [14C]-BI 10773 - oral solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02220920
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients will receive Placebo orally for 16 weeks
Trial: NCT03198715
Drug: DS1040b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DS-1040b in solution for intravenous infusion
Trial: NCT03198715
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline solution for intravenous infusion
Trial: NCT02040415
Drug: Myonal Tab.(eperisone HCl) 50mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02040415
Drug: Placebo drug of Myonal Tab.
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02135432
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00253747
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OROS-MPH (placebo) dosing strategy will start with 18 mg/day for 3 days, increasing to 36mg/day for the next three days; increasing to 54 mg/day in week two, and to 72 mg/day in week three through the remainder of the study (as tolerated). And, nicotine patch dosing schedule will be 21 mg/day during weeks 4-11; 14 mg/day during weeks 12-13; and 7 mg/day in week 14.
Trial: NCT01917396
Drug: Fleet enema
RxNorm normalized name: Fleet Enema
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02433418
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Women will receive oral diclofenac 50 mg (voltaren ®) 1 hour before hysterosalpingography
Trial: NCT04501523
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600-750 mg/m2 PO Bid，continuous, for 1 year
Trial: NCT03776968
Drug: HC1119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT01733758
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albiglutide matching placebo will be available as a pen injector
Trial: NCT01399619
Drug: PegIFN/RBV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PegIFN/RBV for 24 or 48w
Trial: NCT01399619
Drug: BI201335
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI201335 for 12w
Trial: NCT01399619
Drug: BI201335 24W
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI201335 for 24w
Trial: NCT02435992
Drug: RPC1063
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02435992
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03879772
Drug: Placebo nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intranasal administration
Trial: NCT00183040
Drug: Topical testosterone
RxNorm normalized name: testosterone Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01780506
Drug: E/C/F/TAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150/150/200/10 mg FDC tablet administered orally once daily
Trial: NCT01780506
Drug: E/C/F/TDF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150/150/200/300 mg FDC tablet administered orally once daily
Trial: NCT01780506
Drug: E/C/F/TDF Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet administered orally once daily
Trial: NCT01780506
Drug: E/C/F/TAF Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet administered orally once daily
Trial: NCT04468139
Drug: Zinc
RxNorm normalized name: Zinc
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: zinc 50 mg orally daily dose will be taken orally by proven COVID-19 cases intervention
Trial: NCT01851824
Drug: acenocoumarol
RxNorm normalized name: acenocoumarol
DrugBank: Acenocoumarol (DB01418)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg single oral doses on Days 1 and 23
Trial: NCT03568136
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for injection in pre-filled syringe
Trial: NCT02086240
Drug: XBD173
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XBD173 (Emapunil is an anxiolytic drug which acts as a selective agonist at the peripheral benzodiazepine receptor), a drug which binds the TSPO with high affinity.
Trial: NCT00450814
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03450161
Drug: Fentanyl dosing schemes
RxNorm normalized name: fentanyl Metered Dose Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: We routinely use fentanyl as the opioid of choice in CABG surgery. However, how much and whether or not to apply it in boli or continuously remain uncertain. We will apply 3 routinely used fentanyl dosing schemes in our hospital. To blind care-givers and patients, in each of the arms a bolus and a continous injection will occur, as delineated in the treatment arms.
Trial: NCT03777982
Drug: LHRH Agonist or Antagonist
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luteinizing hormone-releasing hormone (LHRH) agonists (also called LHRH analogs or GnRH agonists) are drugs that lower the amount of testosterone made by the testicles
Trial: NCT00066274
Drug: FOLFIRI regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03969212
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IPs less than 12 years old will receive placebo oral suspension and those above 12 years will receive placebo tablets. HHCs of IPs will not receive study medication.
Trial: NCT00678782
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (NaCl) 0.5 ml intraarticular injection
Trial: NCT03755934
Drug: MEDI7352
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive IV infusion of MEDI7352 as stated in arm description.
Trial: NCT00066274
Drug: FOLFOX regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00066274
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00066274
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03113773
Drug: Placebo Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextrose 5%
Trial: NCT02103894
Drug: [18F]T807 ([18F]MNI-777)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All enrolled subjects will undergo an \[18F\]MNI-777 PET imaging visit. For individuals with AD or CTE, \[18F\]florbetapir imaging may also be performed to serve as a means of correlating disease severity by evaluating the relationship of β-amyloid uptake (measured by \[18F\]florbetapir imaging) and tau protein uptake (measured by \[18F\]MNI-777 PET imaging). For individuals with Parkinsonian symptoms, \[123I\]β-CIT SPECT imaging may be performed to evaluate for a reduction in dopamine transporter uptake.
Trial: NCT01069003
Drug: Placebo Arm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo and ASA (75 mg - 325 mg)
Trial: NCT01069003
Drug: Thienopyridine Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel 5 or 10 mg or Clopidogrel 75 mg plus ASA (75 mg - 325 mg)
Trial: NCT04345120
Drug: SY-008 matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SY-008 matching placebo
Trial: NCT00551642
Drug: Nitric oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitric Oxide vapour (gas) for inhalation (400 ppm)
Trial: NCT00551642
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gas for inhalation
Trial: NCT01992146
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02269969
Drug: Tobramycin
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00125255
Drug: S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-Caine Peel comprising of a 1:1 eutectic mixture of 7% lidocaine and 7% tetracaine was applied topically. The study drug was applied at approximately 1 mm in thickness and remained on the treatment area for 30 minutes
Trial: NCT00125255
Drug: Placebo Peel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Peel applied topically at approximately 1 mm in thickness and remained on the treatment area for 30 minutes
Trial: NCT02072668
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject will receive rivaroxaban 20mg PO daily for 4 weeks and then matching placebo 1 PO daily for 4 weeks, with a 2-week wash out period in between the two treatment phases. Both of the two treatments will be in capsule form OR Subject will receive placebo 1 PO daily for 4 weeks, then rivaroxaban 20mg PO daily for 4 weeks, with a 2-week wash out period in between the two treatment phases. Both of the two treatments will be in capsule form.
Trial: NCT00429026
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 60 mg/kg IV Daily for 2 Days
Trial: NCT00974792
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00974792
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00974792
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00974792
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00628420
Drug: ACP-104
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25mg, 75mg, 125mg, 175mg, 225mg, or 275mg once a day for 2 weeks
Trial: NCT00628420
Drug: ACP-104
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient will be given either 50mg, 100mg, 150mg, 200mg, 250mg, or 300mg daily for 2 weeks
Trial: NCT00628420
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients will be given a placebo: 25mg, 50mg, 75mg, 100mg, 125mg, 150mg, 175mg, 200mg, 225mg, 250mg, 275mg, or 300mg (to match the doses given) daily for 2 weeks.
Trial: NCT01457703
Drug: Recombinant LH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Used to stimulate ovarian function in women.
Trial: NCT00632229
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pill placebo taken daily ranging from 3-9mg/day depending on tolerability and efficacy.
Trial: NCT03000608
Drug: SAN021 Serum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAN021 is a serum containing 10% East Indian Sandalwood Oil. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
Trial: NCT03000608
Drug: SAN021 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAN021 Placebo is a serum that does not contain East Indian Sandalwood Oil however, does contain a synthetic sandalwood fragrance. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
Trial: NCT02743052
Drug: Anticoagulation treatment.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Details of anticoagulation treatment information will be gathered including low molecular-weight heparin (enoxaparin 1 mg/kg) vs. NOAC (rivaroxaban 15 or 20 mg), vs. warfarin (target INR2.0-3.0) or no use of anticoagulation per physicians' decision and patients' conditions.
Trial: NCT04964180
Drug: Indomethacin suppository
RxNorm normalized name: indomethacin Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two 100 mg indomethacin rectal suppositories 2 hours prior to surgery
Trial: NCT01817153
Drug: hydrocortison hemisuccinate
RxNorm normalized name: Hydrocortisone Hemisuccinate
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01817153
Drug: placebo followed by hydrocortisone hemisuccinate
RxNorm normalized name: Hydrocortisone Hemisuccinate
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01694849
Drug: GFT505 80mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01694849
Drug: GFT505 120mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01694849
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00766870
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Per oral doses, twice daily as capsules during 10 weeks
Trial: NCT01770080
Drug: Euminz®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 to 5 time topical use of study drug.
Trial: NCT01770080
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 to 5 time topical use of study drug.
Trial: NCT02858622
Drug: perfalgan
RxNorm normalized name: PERFALGAN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous paracetamol
Trial: NCT02858622
Drug: fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01723982
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01258803
Drug: Placebo MDI without spacer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two inhalations of placebo MDI administered as a single dose without an AeroChamber Plus® Flow-Vu® Anti-Static Valved Holding Chamber (spacer)
Trial: NCT01263366
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Approximately 1.6 or 4.6 mL of a 400 mM norepinephrine solution will be applied topically to a portion of the radiation treatment field prior to each radiation treatment (20-33 treatments)
Trial: NCT03817658
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First stage：~Concurrent chemoradiotherapy:~Cisplatin：25-30mg/m2 ivgtt d1;Capecitabine：800mg/m2, bid d1-5，qw，5weeks；Synchronous radiotherapy：1.8-2Gy/d，5d/W，45-50Gy。 Consolidation treatment： Cisplatin： 60-75mg/m2 ivgtt d1 Capecitabine：1000mg/m2, bid d1-14，q3w 6weeks。~Second stage:~Placebo was administered intravenously (no prophylactic use), a fixed dose of 200 mg, and 3 mg/kg for subjects with a baseline weight \<50 kg. Each infusion for 30 min (not less than 20 min, no more than 60 min), once every 2 weeks, 1 cycle every 4 weeks, the cumulative longest medication period is 12 months.
Trial: NCT01678287
Drug: ASP1941
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT01678287
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT00779142
Drug: Methotrexate intravenous 25mg/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate intravenous 25mg/ml delivered once or twice (based on the therapeutic response) over a period of 2 months maximum. Total dosage 400ug in each dose. Statistical analysis would not be applicable in this small sample.
Trial: NCT01348074
Drug: Double dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For each individual the dose on Day 1 and Day 2 will be twice the one normally taken
Trial: NCT02233686
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03955146
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching to pamrevlumab will be administered per schedule specified in the arm description.